ArticleThe Pan African medical journal2022
[Humoral response to
Article in The Pan African medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: vaccines are the key tools for controlling and eradicating malaria worldwide. Currently, research and development are focused on three types of vaccine candidates that target different life stages of Plasmodium falciparum in humans and the vector. The purpose of this study is to evaluate the humoral response to Plasmodium falciparum antigenic peptides (MSP1, MSP2 and SR-11.1) in subjects living in endemic areas. Methods: we conducted a cross-sectional study of serum samples collected from 182 Vietnamese subjects living in endemic areas over a period of 5 months. Whole blood was centrifuged and the serum was aliquoted into cryovials and preserved at -20°C until IgG testing. ELISA was used for total immunoglobulin G (IgG) antibodies testing after peptide coupling with glutaraldehyde. Results: a total of 182 sera samples from Vietnamese subjects living in endemic areas were included. In the different study age groups, total antigen-specific IgG antibodies against Plasmodium falciparum antigenic peptides (MSP-1; MSP-2 and SR-11.1) showed age-dependent distribution. In subjects aged 3-19 years, the level of total antigen-specific IgG antibodies against Plasmodium falciparum were lower than those of the age groups over 20 years of age (p=0.07). Comparison of specific antigen-specific IgG antibody levels with Plasmodium falciparum antigenic peptides MSP-1, MSP-2, and SR-11.1 in the age groups showed a significantly higher mean in MSP-1 and MSP-2 compared to anti-SR-11.1 (p=0.04). Conclusion: this study highlights that the level of specific antibodies against Plasmodium falciparum antigenic peptides (MSP-1; MSP-2 and SR-11.1) is age dependent. Of the three antigenic peptides, MSP-1 and MSP-2 appear to be more immunogenic than SR.11.1. Therefore, SR.11.1 is a macromolecule to the immune system and, from this point of view, appears to be significantly less immunogenic than other peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.